• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

    5/5/25 8:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBIO alert in real time by email
    • Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle
    • Strong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone

    SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in January. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-digit weight reductions typically required by other obesity drugs.

    GLP-1 receptor agonists are effective at promoting weight loss. However, they can also reduce lean body mass, including muscle, which may limit some of the intended health benefits. In contrast, fat-specific weight loss is considered a higher-quality form of weight loss. It reduces fat—linked to lower risk of heart and metabolic diseases—while preserving muscle, which helps maintain strength, supports a healthy metabolism, and may prevent or reduce weight regain over time.

    "We believe achieving high-quality weight loss, by reducing fat mass while preserving muscle, is essential in addressing the obesity epidemic," said Martin Brenner, DVM, PhD, Chief Executive Officer and Chief Scientific Officer of iBio. "For example, a person with a BMI of 30 is classified as obese and often has a body fat percentage exceeding 25%. Reducing fat by 25% while maintaining muscle mass and strength could shift them into a healthier weight category without compromising physical function."

    The study also analyzed specific fat depots in obese mice and found a significant 31% reduction in subcutaneous fat. More notably, reductions of 34% and 37% were observed in the epididymal and retroperitoneal fat depots, respectively—both of which are forms of visceral fat closely linked to increased risk of cardiometabolic disease. When combined with a GLP-1 receptor agonist, the Activin E antibody produced additive effects, reducing total fat mass by 77%. Subcutaneous fat loss increased to 74%, while visceral fat depots—epididymal and retroperitoneal—were reduced by 69% and 81%, respectively. The data was presented at the 14th International BMP Conference that occurred May 2–6 in Philadelphia, Pennsylvania.

    About iBio, Inc.

    iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.  For more information, visit www.ibioinc.com or follow us on LinkedIn.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the therapeutic potential of Activin E as a target for cardiometabolic disorders and obesity; Activin E being a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease; plans to rapidly advance testing of the antibody in more complex models; the in-licensed antibody being the first functional inhibitor of Activin E; inhibiting Activin E-mediated signaling offering a novel therapeutic strategy to reduce internal abdominal fat while preserving muscle mass potentially reversing obesity, preventing diabetes, and improving overall cardiometabolic health. As one of several cellular components involved in cardiometabolic regulation; Activin E, along with amylin, GLP-1 and others, having the potential to be targeted simultaneously to yield synergistic benefits for patients; and the antibody having the potential to deliver meaningful benefits to patients. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of Activin E to be a successful target for cardiometabolic disorders and obesity and iBio's antibody to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease; iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

    Corporate Contact:

    iBio, Inc.

    Investor Relations

    [email protected]

    Media Contacts:

    Ignacio Guerrero-Ros, Ph.D., or David Schull

    Russo Partners, LLC

    [email protected]

    [email protected]

    (858) 717-2310 or (646) 942-5604



    Primary Logo

    Get the next $IBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IBIO

    DatePrice TargetRatingAnalyst
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    More analyst ratings

    $IBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • iBio to Begin Trading on the Nasdaq Stock Exchange

      SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

      2/19/25 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Strengthens Board with Appointment of Two New Independent Directors

      SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

      11/25/24 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal First Quarter 2025 Financial Results

      SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and

      11/12/24 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on iBio with a new price target

      Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00

      5/28/24 7:42:07 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Mkt Outperform and set a new price target of $1.50

      11/29/21 7:34:24 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Outperform and set a new price target of $1.50

      11/29/21 7:32:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IBIO
    SEC Filings

    See more

    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

      Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in Janu

      5/5/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal Third Quarter 2025 Financial Results

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. "During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "At the same time, we made significant strides in our pipeline, with promising non

      5/2/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Raises $6.2 Million Through Warrant Inducement Transaction

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase 5,626,685 shares of common stock at a reduced exercise price of $1.11 per share, resulting in gross proceeds of approximately $6.2 million, before deducting advisory fees and certain other expenses. The Company intends to use the net proceeds for worki

      4/29/25 1:43:30 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by iBio Inc.

      D - iBio, Inc. (0001420720) (Filer)

      5/7/25 9:50:45 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by iBio Inc.

      10-Q - iBio, Inc. (0001420720) (Filer)

      5/2/25 8:29:28 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - iBio, Inc. (0001420720) (Filer)

      5/2/25 8:05:54 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      11/14/24 8:47:49 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iBio Inc.

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      11/14/24 4:48:52 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by iBio Inc. (Amendment)

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      4/9/24 5:22:43 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:37 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:02 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:33:31 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Financials

    Live finance-specific insights

    See more
    • iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

      – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,

      3/27/24 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

      BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. "We have continued to take important steps toward achieving our strategic objective of becoming a leading biotechnology company with a focus on developing innovative immunotherapies," said Tom Isett, Chairman & CEO of iBio. "Chief among these was the RubrYc asset acquisition, which provides us with a differentiated, AI-powered drug di

      9/27/22 4:10:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

      – Positions Company for leadership in AI-powered drug discovery – – Expands iBio's immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company's transformation and FY2022 financial results – SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ("RubrYc") after it entered into a definitive asset purchase agreement (the

      9/21/22 8:30:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Legal Officer Banjak Marc

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:01:30 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Duran Felipe

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:59 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Brenner Martin

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:12 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care